Page 81 - 《中国药房》2023年2期

参考文献 JAMA，2001，285（19）：2486-2497.
[ 1 ] OWEN M J，SAWA A，MORTENSEN P B. Schizophrenia [13] 中华医学会精神医学分会精神分裂症协作组.精神分裂
[J]. Lancet，2016，388（10039）：86-97. 症患者代谢综合征管理的中国专家共识[J]. 中华精神科
[ 2 ] MILLARD S J，BEARDEN C E，KARLSGODT K H，et 杂志，2020，53（1）：3-10.
al. The prediction-error hypothesis of schizophrenia：new [14] LUO C，LIU J，WANG X Y，et al. Pharmacogenetic corre‐
data point to circuit-specific changes in dopamine activity lates of antipsychotic-induced weight gain in the Chinese
[J]. Neuropsychopharmacology，2022，47（3）：628-640. population[J]. Neurosci Bull，2019，35（3）：561-580.
[ 3 ] STROUP T S，GERHARD T，CRYSTAL S，et al. Com‐ [15] 邵青，张晓红，权伟，等. 抗精神病药物引起的不良反应
parative effectiveness of clozapine and standard antipsy‐ 回顾性分析[J]. 中国医药导报，2021，18（14）：156-159.
chotic treatment in adults with schizophrenia[J]. Am J Psy‐ [16] VANCAMPFORT D，STUBBS B，MITCHELL A J，et al.
chiatry，2016，173（2）：166-173. Risk of metabolic syndrome and its components in people
[ 4 ] CHOUINARD G，SAMAHA A N，CHOUINARD V A，et with schizophrenia and related psychotic disorders，bipo‐
al. Antipsychotic-induced dopamine supersensitivity psy‐ lar disorder and major depressive disorder：a systematic re‐
chosis：pharmacology，criteria，and therapy[J]. Psychother view and meta-analysis[J]. World Psychiatry，2015，14
（3）：339-347.
Psychosom，2017，86（4）：189-219.
[17] PAN L，YANG Z H，WU Y，et al. The prevalence，aware‐
[ 5 ] IJAZ S，BOLEA B，DAVIES S，et al. Antipsychotic poly‐
ness，treatment and control of dyslipidemia among adults
pharmacy and metabolic syndrome in schizophrenia：a re‐
in China[J]. Atherosclerosis，2016，248（3）：2-9.
view of systematic reviews[J]. BMC Psychiatry，2018，18
[18] MENG Q H，LI J，CHAO Y，et al. β-estradiol adjusts in‐
（1）：275-288.
testinal function via ERβ and GPR30 mediated PI3K/Akt
[ 6 ] 中华医学会糖尿病学分会 . 中国 2 型糖尿病防治指南：
signaling activation to alleviate postmenopausal dyslipi-
2020年版[J].中华糖尿病杂志，2021，13（4）：315-409.
demia[J]. Biochem Pharmacol，2020，180：114134.
[ 7 ] PENNINX B W J H，LANGE S M M. Metabolic syn‐
[19] OISHI K，NIITSU T，KANAHARA N，et al. Genetic risks
drome in psychiatric patients：overview，mechanisms，and
of schizophrenia identified in a matched case-control study
implications[J]. Dialogues Clin Neurosci，2018，20（1）：
[J]. Eur Arch Psychiatry Clin Neurosci，2021，271（4）：
63-73.
775-781.
[ 8 ] NYMBERG C，BANASCHEWSKI T，BOKDE A L，et al.
[20] ALIASGHARI F，NAZM S A，YASARI S，et al. Associa‐
DRD2/ANKK1 polymorphism modulates the effect of
tions of the ANKK1 and DRD2 gene polymorphisms with
ventral striatal activation on working memory performance
overweight，obesity and hedonic hunger among women
[J]. Neuropsychopharmacology，2014，39（10）：2357-2365.
from the Northwest of Iran[J]. Eat Weight Disord，2021，
[ 9 ] ALIASGHARI F，MAHDAVI R，BARATI M，et al. Geno‐
26（1）：305-312.
types of ANKK1 and DRD2 genes and risk of metabolic
[21] CARDEL M I，LEMAS D J，LEE A M，et al. Taq1A poly‐
syndrome and its components：a cross-sectional study on
morphism（rs1800497）is associated with obesity-related
Iranian women[J]. Obes Res Clin Pract，2021，15（5）：
outcomes and dietary intake in a multi-ethnic sample of
449-454.
children[J]. Pediatr Obes，2019，14（2）：e12470.
[10] PINTO J A F，FREITAS P H B，NUNES F D D，et al.
[22] HENI M，KULLMANN S，AHLQVIST E，et al. Interac‐
Prevalence of polymorphisms in the ANKK1，DRD2，
tion between the obesity-risk gene FTO and the dopamine
DRD3 genes and metabolic syndrome in refractory schizo‐
D2 receptor gene ANKK1/Taq1A on insulin sensitivity[J].
phrenia[J]. Rev Lat Am Enfermagem，2018，26：e2983.
Diabetologia，2016，59（12）：2622-2631.
[11] ENGELKE R，OUANES S，GHULOUM S，et al. Pro‐ [23] MULLALLY J A，CHUNG W K，LEDUC C A，et al.
teomic analysis of plasma markers in patients maintained Weight-loss response to naltrexone/bupropion is modu‐
on antipsychotics：comparison to patients off antipsycho- lated by the Taq1A genetic variant near DRD2（rs1800497）：
tics and normal controls[J]. Front Psychiatry，2022，13： a pilot study[J]. Diabetes Obes Metab，2021，23（3）：850-853.
809071. [24] LUQUAIN-COSTAZ C，KOCKX M，ANASTASIUS M，
[12] EXPERT PANEL on DETECTION，EVALUATION，and et al. Increased ABCA1（ATP-binding cassette transporter
TREATMENT of HIGH BLOOD CHOLESTEROL in A1）-specific cholesterol efflux capacity in schizophrenia
ADULTS. Executive summary of the third report of the [J]. Arterioscler Thromb Vasc Biol，2020，40（11）：2728-
national cholesterol education program（NCEP）expert 2737.
panel on detection，evaluation，and treatment of high （收稿日期：2022-06-18 修回日期：2022-11-01）
blood cholesterol in adults：Adult Treatment Panel Ⅲ[J]. （编辑：张元媛，邹丽娟）

中国药房 2023年第34卷第2期 China Pharmacy 2023 Vol. 34 No. 2 · 199 ·